78 results on '"Kakkola L"'
Search Results
2. Replication of and Protein Synthesis by TT Viruses
- Author
-
Kakkola, L., Hedman, K., Qiu, J., Pintel, D., S”derlund-Venermo, M., Compans, Richard W., editor, Cooper, Max D., editor, Honjo, Tasuku, editor, Koprowski, Hilary, editor, Melchers, Fritz, editor, Oldstone, Michael B. A., editor, Olsnes, Michael Sjur, editor, Vogt, Peter K., editor, de Villiers, Ethel-Michele, editor, and Hausen, Harald zur, editor
- Published
- 2009
- Full Text
- View/download PDF
3. Genoprevalence in human tissues of TT-virus genotype 6
- Author
-
Kakkola, L., Kaipio, N., Hokynar, K., Puolakkainen, P., Mattila, P. S., Kokkola, A., Partio, E. K., Eis-Hübinger, A.-M., Söderlund-Venermo, M., and Hedman, K.
- Published
- 2004
- Full Text
- View/download PDF
4. ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER
- Author
-
PALMBERG, C., KOIVISTO, P., KAKKOLA, L., TAMMELA, T.L.J., KALLIONIEMI, O.P., and VISAKORPI, T.
- Published
- 2000
- Full Text
- View/download PDF
5. Expression of Ebola and Marburg virus proteins and their effect on activation of innate interferon responses
- Author
-
Kakkola, L., primary, He, F., additional, Maljanen, S., additional, Melén, K., additional, Airenne, K., additional, Vapalahti, O., additional, and Julkunen, I., additional
- Published
- 2015
- Full Text
- View/download PDF
6. Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice
- Author
-
Kakkola, L, primary, Denisova, O V, additional, Tynell, J, additional, Viiliäinen, J, additional, Ysenbaert, T, additional, Matos, R C, additional, Nagaraj, A, additional, Öhman, T, additional, Kuivanen, S, additional, Paavilainen, H, additional, Feng, L, additional, Yadav, B, additional, Julkunen, I, additional, Vapalahti, O, additional, Hukkanen, V, additional, Stenman, J, additional, Aittokallio, T, additional, Verschuren, E W, additional, Ojala, P M, additional, Nyman, T, additional, Saelens, X, additional, Dzeyk, K, additional, and Kainov, D E, additional
- Published
- 2013
- Full Text
- View/download PDF
7. Human torque teno virus (TTV): expression of proteins for immunoassays
- Author
-
Kakkola, L., primary, Bondén, H., additional, Hedman, L., additional, Kantola, K., additional, Julin, J., additional, Moisala, S., additional, Ylä-Liedenpohja, J., additional, Miettinen, S., additional, Söderlund-Venermo, M., additional, and Hedman, K., additional
- Published
- 2006
- Full Text
- View/download PDF
8. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones
- Author
-
Kevin E. Brown, Susan Wong, Claudia Filippone, Laura Kakkola, Neal S. Young, Maria Söderlund-Venermo, Giorgio Gallinella, Jun Lu, Ning Zhi, Sachiko Kajigaya, Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, Kakkola L, Söderlund-Venermo M, Young NS, and Brown KE
- Subjects
Infectious clone ,viruses ,Molecular Sequence Data ,Genome, Viral ,Parvovirus B19 ,Biology ,Article ,Virus ,Cell Line ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Plasmid ,law ,Virology ,Parvovirus B19, Human ,Humans ,Amino Acid Sequence ,Cloning, Molecular ,Child ,Peptide sequence ,030304 developmental biology ,Infectivity ,0303 health sciences ,Parvovirus ,Nucleic acid sequence ,Sequence Analysis, DNA ,biology.organism_classification ,Molecular biology ,PLA2-like motif ,3. Good health ,Phospholipases A2 ,Capsid ,030220 oncology & carcinogenesis ,Mutation ,Recombinant DNA ,Capsid Proteins - Abstract
Three full-length genomic clones (pB19-M20, pB19-FL and pB19-HG1) of parvovirus B19 were produced in different laboratories. pB19-M20 was shown to produce infectious virus. To determine the differences in infectivity, all three plasmids were tested by transfection and infection assays. All three clones were similar in viral DNA replication, RNA transcription, and viral capsid protein production. However, only pB19-M20 and pB19-HG1 produced infectious virus. Comparison of viral sequences showed no significant differences in ITR or NS regions. In the capsid region, there was a nucleotide sequence difference conferring an amino acid substitution (E176K) in the phospholipase A2-like motif of the VP1-unique (VP1u) region. The recombinant VP1u with the E176K mutation had no catalytic activity as compared with the wild-type. When this mutation was introduced into pB19-M20, infectivity was significantly attenuated, confirming the critical role of this motif. Investigation of the original serum from which pB19-FL was cloned confirmed that the phospholipase mutation was present in the native B19 virus.
- Published
- 2008
9. High Glucose Increases Lactate and Induces the Transforming Growth Factor Beta-Smad 1/5 Atherogenic Pathway in Primary Human Macrophages.
- Author
-
Awad K, Kakkola L, and Julkunen I
- Abstract
Hundreds of millions of people worldwide are expected to suffer from diabetes mellitus. Diabetes is characterized as a dynamic and heterogeneous disease that requires deeper understanding of the pathophysiology, genetics, and metabolic shaping of this disease and its macro/microvascular complications. Macrophages play an essential role in regulating local immune responses, tissue homeostasis, and disease pathogenesis. Here, we have analyzed transforming growth factor beta 1 (TGFβ1)/Smad signaling in primary human macrophages grown in normal (NG) and high-glucose (HG; +25 mM glucose) conditions. Cell culture lactate concentration and cellular phosphofructokinase (PFK) activity were increased in HG concentrations. High glucose levels in the growth media led to increased macrophage mRNA expression of TGFβ1, and TGFβ-regulated HAMP and PLAUR mRNA levels, while the expression of TGFβ receptor II remained unchanged. Stimulation of cells with TGFβ1 protein lead to Smad2 phosphorylation in both NG and HG conditions, while the phosphorylation of Smad1/5 was detected only in response to TGFβ1 stimulation in HG conditions. The use of the specific Alk1/2 inhibitor dorsomorphin and the Alk5 inhibitor SB431542, respectively, revealed that HG conditions led TGFβ1 to activation of Smad1/5 signaling and its downstream target genes. Thus, high-glucose activates TGFβ1 signaling to the Smad1/5 pathway in primary human macrophages, which may contribute to cellular homeostasis in a harmful manner, priming the tissues for diabetic complications.
- Published
- 2024
- Full Text
- View/download PDF
10. Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection.
- Author
-
Reinholm A, Maljanen S, Jalkanen P, Altan E, Tauriainen S, Belik M, Skön M, Haveri A, Österlund P, Iakubovskaia A, Pasternack A, Naves RA, Ritvos O, Miettinen S, K Häkkinen H, Ivaska L, Tähtinen PA, Lempainen J, Kantele A, Kakkola L, Julkunen I, and Kolehmainen P
- Abstract
Background: Vaccinations against the SARS-CoV-2 are still crucial in combating the ongoing pandemic that has caused more than 700 million infections and claimed almost 7 million lives in the past four years. Omicron (B.1.1.529) variants have incurred mutations that challenge the protection against infection and severe disease by the current vaccines, potentially compromising vaccination efforts., Methods: We analyzed serum samples taken up to 9 months post third dose from 432 healthcare workers. Enzyme-linked immunosorbent assays (ELISA) and microneutralization tests (MNT) were used to assess the prevalence of vaccine-induced neutralizing antibodies against various SARS-CoV-2 Omicron variants., Results: In this serological analysis we show that SARS-CoV-2 vaccine combinations of BNT162b2, mRNA-1273, and ChAdOx1 mount SARS-CoV-2 binding and neutralizing antibodies with similar kinetics, but with differing neutralization capabilities. The most recent Omicron variants, BQ.1.1 and XBB.1.5, show a significant increase in the ability to escape vaccine and infection-induced antibody responses. Breakthrough infections in thrice vaccinated adults were seen in over 50% of the vaccinees, resulting in a stronger antibody response than without infection., Conclusions: Different three-dose vaccine combinations seem to induce considerable levels of neutralizing antibodies against most SARS-CoV-2 variants. However, the ability of the newer variants BQ1.1 and XBB 1.5 to escape vaccine-induced neutralizing antibody responses underlines the importance of updating vaccines as new variants emerge., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
11. Emerging Microbes, Infections, and Spillovers: Charting a Path Forward.
- Author
-
Grzybek M, Kakkola L, Sironen T, and Kant R
- Subjects
- Humans, Communicable Diseases epidemiology
- Abstract
In an age defined by rapid globalization and unprecedented technological advancements, the field of infectious diseases stands at the intersection of complex challenges and promising opportunities [...].
- Published
- 2023
- Full Text
- View/download PDF
12. Insights into COVID-19: Perspectives on Drug Remedies and Host Cell Responses.
- Author
-
Awad AM, Hansen K, Del Rio D, Flores D, Barghash RF, Kakkola L, Julkunen I, and Awad K
- Subjects
- Humans, SARS-CoV-2 metabolism, Peptidyl-Dipeptidase A chemistry, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Virus Internalization, COVID-19
- Abstract
In light of the COVID-19 global pandemic caused by SARS-CoV-2, ongoing research has centered on minimizing viral spread either by stopping viral entry or inhibiting viral replication. Repurposing antiviral drugs, typically nucleoside analogs, has proven successful at inhibiting virus replication. This review summarizes current information regarding coronavirus classification and characterization and presents the broad clinical consequences of SARS-CoV-2 activation of the angiotensin-converting enzyme 2 (ACE2) receptor expressed in different human cell types. It provides publicly available knowledge on the chemical nature of proposed therapeutics and their target biomolecules to assist in the identification of potentially new drugs for the treatment of SARS-CoV-2 infection.
- Published
- 2023
- Full Text
- View/download PDF
13. Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.
- Author
-
Pietiäinen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, Turunen L, Hassinen A, Potdar S, Koponen A, Sebestyen EG, Kovacs F, Kriston A, Hollandi R, Burian K, Terhes G, Visnyovszki A, Fodor E, Lacza Z, Kantele A, Kolehmainen P, Kakkola L, Strandin T, Levanov L, Kallioniemi O, Kemeny L, Julkunen I, Vapalahti O, Buzas K, Paavolainen L, Horvath P, and Hepojoki J
- Subjects
- Humans, COVID-19 Testing, Acclimatization, Machine Learning, SARS-CoV-2, COVID-19
- Abstract
We present a miniaturized immunofluorescence assay (mini-IFA) for measuring antibody response in patient blood samples. The method utilizes machine learning-guided image analysis and enables simultaneous measurement of immunoglobulin M (IgM), IgA, and IgG responses against different viral antigens in an automated and high-throughput manner. The assay relies on antigens expressed through transfection, enabling use at a low biosafety level and fast adaptation to emerging pathogens. Using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the model pathogen, we demonstrate that this method allows differentiation between vaccine-induced and infection-induced antibody responses. Additionally, we established a dedicated web page for quantitative visualization of sample-specific results and their distribution, comparing them with controls and other samples. Our results provide a proof of concept for the approach, demonstrating fast and accurate measurement of antibody responses in a research setup with prospects for clinical diagnostics., Competing Interests: P.H. is the founder and shareholder and A. Kriston and F.K. are employees of Single-Cell Technologies Ltd. This study has been protected with invention disclosures (ID965/2020 and ID115/2021 University of Helsinki, Finland), and the patent application has been filed (Hungary, no. P2100295)., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
14. VP24 matrix proteins of eight filoviruses downregulate innate immune response by inhibiting the interferon-induced pathway.
- Author
-
Khan H, Tripathi L, Kolehmainen P, Lundberg R, Altan E, Heroum J, Julkunen I, Kakkola L, and Huttunen M
- Subjects
- Animals, Nuclear Localization Signals, Immunity, Innate, Interferon-alpha, Antiviral Agents, Viral Matrix Proteins, Mammals, Marburgvirus genetics, Ebolavirus
- Abstract
Filoviruses encode viral protein 24 (VP24) which effectively inhibit the innate immune responses in infected cells. Here we systematically analysed the effects of nine mammalian filovirus VP24 proteins on interferon (IFN)-induced immune response. We transiently expressed Ebola, Bombali, Bundibugyo, Reston, Sudan and Taï Forest ebolavirus (EBOV, BOMV, BDBV, RESTV, SUDV, TAFV, respectively), Lloviu virus (LLOV), Mengla dianlovirus (MLAV) and Marburgvirus (MARV) VP24 proteins and analysed their ability to inhibit IFN-α-induced activation of myxovirus resistance protein 1 (MxA) and interferon-induced transmembrane protein 3 (IFITM3) promoters. In addition, we analysed the expression of endogenous MxA protein in filovirus VP24-expressing cells. Eight filovirus VP24 proteins, including the VP24s of the recently discovered MLAV, BOMV and LLOV, inhibited IFN-induced MxA and IFITM3 promoter activation. MARV VP24 was the only protein with no inhibitory effect on the activation of either promoter. Endogenous MxA protein expression was impaired in cells transiently expressing VP24s with the exception of MARV VP24. We mutated nuclear localization signal (NLS) of two highly pathogenic filoviruses (EBOV and SUDV) and two putatively non-pathogenic filoviruses (BOMV and RESTV), and showed that the inhibitory effect on IFN-induced expression of MxA was dependent on functional cluster 3 of VP24 nuclear localization signal. Our findings suggest that filovirus VP24 proteins are both genetically and functionally conserved, and that VP24 proteins of most filovirus species are capable of inhibiting IFN-induced antiviral gene expression thereby efficiently downregulating the host innate immune responses.
- Published
- 2023
- Full Text
- View/download PDF
15. Coronavirus spike protein-specific antibodies indicate frequent infections and reinfections in infancy and among BNT162b2-vaccinated healthcare workers.
- Author
-
Kolehmainen P, Huttunen M, Iakubovskaia A, Maljanen S, Tauriainen S, Yatkin E, Pasternack A, Naves R, Toivonen L, Tähtinen PA, Ivaska L, Lempainen J, Peltola V, Waris M, Kakkola L, Ritvos O, and Julkunen I
- Subjects
- Adult, Child, Humans, Child, Preschool, Infant, Animals, Guinea Pigs, Rabbits, Reinfection, BNT162 Vaccine, Spike Glycoprotein, Coronavirus, SARS-CoV-2, Antibodies, Viral, Health Personnel, COVID-19 epidemiology, COVID-19 prevention & control, Blood Group Antigens, Coronavirus 229E, Human
- Abstract
The prevalence of seasonal human coronavirus (HCoV) infections in early childhood and adults has not been well analyzed in longitudinal serological studies. Here we analyzed the changes in HCoV (229E, HKU1, NL63, OC43, MERS, and SARS-CoV-2) spike-specific antibody levels in follow-up serum specimens of 140 children at the age of 1, 2, and 3 years, and of 113 healthcare workers vaccinated for Covid-19 with BNT162b2-vaccine. IgG antibody levels against six recombinant HCoV spike subunit 1 (S1) proteins were measured by enzyme immunoassay. We show that by the age of three years the cumulative seropositivity for seasonal HCoVs increased to 38-81% depending on virus type. BNT162b2 vaccinations increased anti-SARS-CoV-2 S1 antibodies, but no increase in seasonal coronavirus antibodies associated with vaccinations. In healthcare workers (HCWs), during a 1-year follow-up, diagnostic antibody rises were seen in 5, 4 and 14% of the cases against 229E, NL63 and OC43 viruses, respectively, correlating well with the circulating HCoVs. In 6% of the HCWs, a diagnostic antibody rise was seen against S1 of HKU1, however, these rises coincided with anti-OC43 S1 antibody rises. Rabbit and guinea pig immune sera against HCoV S1 proteins indicated immunological cross-reactivity within alpha-CoV (229E and NL63) and beta-CoV (HKU1 and OC43) genera., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
16. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
- Author
-
Belik M, Liedes O, Vara S, Haveri A, Pöysti S, Kolehmainen P, Maljanen S, Huttunen M, Reinholm A, Lundberg R, Skön M, Österlund P, Melin M, Hänninen A, Hurme A, Ivaska L, Tähtinen PA, Lempainen J, Kakkola L, Jalkanen P, and Julkunen I
- Subjects
- Humans, Antibodies, Neutralizing, Antibodies, Viral, CD8-Positive T-Lymphocytes, Immunoglobulin G, SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunity, Cellular
- Abstract
Introduction: The prime-boost COVID-19 mRNA vaccination strategy has proven to be effective against severe COVID-19 disease and death. However, concerns have been raised due to decreasing neutralizing antibody levels after COVID-19 vaccination and due to the emergence of new immuno-evasive SARS-CoV-2 variants that may require additional booster vaccinations., Methods: In this study, we analyzed the humoral and cell-mediated immune responses against the Omicron BA.1 and BA.2 subvariants in Finnish healthcare workers (HCWs) vaccinated with three doses of COVID-19 mRNA vaccines. We used enzyme immunoassay and microneutralization test to analyze the levels of SARS-CoV-2 specific IgG antibodies in the sera of the vaccinees and the in vitro neutralization capacity of the sera. Activation induced marker assay together with flow cytometry and extracellular cytokine analysis was used to determine responses in SARS-CoV-2 spike protein stimulated PBMCs., Results: Here we show that within the HCWs, the third mRNA vaccine dose recalls both humoral and T cell-mediated immune responses and induces high levels of neutralizing antibodies against Omicron BA.1 and BA.2 variants. Three weeks after the third vaccine dose, SARS-CoV-2 wild type spike protein-specific CD4
+ and CD8+ T cells are observed in 82% and 71% of HCWs, respectively, and the T cells cross-recognize both Omicron BA.1 and BA.2 spike peptides. Although the levels of neutralizing antibodies against Omicron BA.1 and BA.2 decline 2.5 to 3.8-fold three months after the third dose, memory CD4+ T cell responses are maintained for at least eight months post the second dose and three months post the third vaccine dose., Discussion: We show that after the administration of the third mRNA vaccine dose the levels of both humoral and cell-mediated immune responses are effectively activated, and the levels of the spike-specific antibodies are further elevated compared to the levels after the second vaccine dose. Even though at three months after the third vaccine dose antibody levels in sera decrease at a similar rate as after the second vaccine dose, the levels of spike-specific CD4+ and CD8+ T cells remain relatively stable. Additionally, the T cells retain efficiency in cross-recognizing spike protein peptide pools derived from Omicron BA.1 and BA.2 subvariants. Altogether our results suggest durable cellmediated immunity and protection against SARS-CoV-2., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Belik, Liedes, Vara, Haveri, Pöysti, Kolehmainen, Maljanen, Huttunen, Reinholm, Lundberg, Skön, Österlund, Melin, Hänninen, Hurme, Ivaska, Tähtinen, Lempainen, Kakkola, Jalkanen and Julkunen.)- Published
- 2023
- Full Text
- View/download PDF
17. Serological Follow-Up Study Indicates High Seasonal Coronavirus Infection and Reinfection Rates in Early Childhood.
- Author
-
Kolehmainen P, Heroum J, Jalkanen P, Huttunen M, Toivonen L, Marjomäki V, Waris M, Smura T, Kakkola L, Tauriainen S, Peltola V, and Julkunen I
- Subjects
- Antibodies, Viral, Child, Child, Preschool, Follow-Up Studies, Humans, Prospective Studies, Reinfection, Seasons, COVID-19, Coronavirus 229E, Human
- Abstract
Seasonal human coronaviruses (HCoVs) cause respiratory infections, especially in children. Currently, the knowledge on early childhood seasonal coronavirus infections and the duration of antibody levels following the first infections is limited. Here we analyzed serological follow-up samples to estimate the rate of primary infection and reinfection(s) caused by seasonal coronaviruses in early childhood. Serum specimens were collected from 140 children at ages of 13, 24, and 36 months (1, 2, and 3 years), and IgG antibody levels against recombinant HCoV nucleoproteins (N) were measured by enzyme immunoassay (EIA). Altogether, 84% (118/140) of the children were seropositive for at least one seasonal coronavirus N by the age of 3 years. Cumulative seroprevalences for HCoVs 229E, HKU1, NL63, and OC43 increased by age, and they were 45%, 27%, 70%, and 44%, respectively, at the age of 3 years. Increased antibody levels between yearly samples indicated reinfections by 229E, NL63, and OC43 viruses in 20-48% of previously seropositive children by the age of 3 years. Antibody levels declined 54-73% or 31-77% during the year after seropositivity in children initially seropositive at 1 or 2 years of age, respectively, in case there was no reinfection. The correlation of 229E and NL63, and OC43 and HKU1 EIA results, suggested potential cross-reactivity between the N specific antibodies inside the coronavirus genera. The data shows that seasonal coronavirus infections and reinfections are common in early childhood and the antibody levels decline relatively rapidly. IMPORTANCE The rapid spread of COVID-19 requires better knowledge on the rate of coronavirus infections and coronavirus specific antibody responses in different population groups. In this work we analyzed changes in seasonal human coronavirus specific antibodies in young children participating in a prospective 3-year serological follow-up study. We show that based on seropositivity and changes in serum coronavirus antibody levels, coronavirus infections and reinfections are common in early childhood and the antibodies elicited by the infection decline relatively rapidly. These observations provide further information on the characteristics of humoral immune responses of coronavirus infections in children.
- Published
- 2022
- Full Text
- View/download PDF
18. Low pre-vaccination SARS-CoV-2 seroprevalence in Finnish health care workers: a prospective cohort study.
- Author
-
Tähtinen PA, Ivaska L, Jalkanen P, Kakkola L, Kainulainen L, Hytönen J, Vuorinen T, Waris M, Peltola V, Oksi J, Julkunen I, and Lempainen J
- Subjects
- Antibodies, Viral, Finland epidemiology, Health Personnel, Humans, Nucleoproteins, Prospective Studies, Seroepidemiologic Studies, Spike Glycoprotein, Coronavirus, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, SARS-CoV-2
- Abstract
Background: Health care workers are at risk of acquiring SARS-CoV-2 infection. Our aim was to study the prevalence of SARS-CoV-2 nucleoprotein and spike protein specific antibodies in health care workers with occupational exposure to COVID-19 in Turku, Finland, from May to December 2020., Methods: Health care workers of Turku University Hospital units caring for COVID-19 patients or handling clinical SARS-CoV-2 samples were invited to participate in the study. The presence of SARS-CoV-2 nucleoprotein and spike protein specific IgG antibodies were analysed with in-house enzyme immunoassay., Results: At study enrolment, only one of the 222 (0.5%) study participants was seropositive for SARS-CoV-2 protein specific antibodies. Two additional study participants (2/222, 0.9%) seroconverted during the follow-up. All these participants were diagnosed with a RT-PCR-positive COVID-19 infection before turning seropositive., Conclusion: In our study population, the prevalence of SARS-CoV-2 seropositivity remained low. The absence of seropositive cases without previous RT-PCR confirmed infections demonstrate good access to diagnostics. In addition to high vaccine coverage, high standards of infection prevention practices and use of standard personal protective equipment seem sufficient in preventing occupational SARS-CoV-2 infection in a setting with low number of circulating virus. However, it remains unclear whether similar protective practices would also be effective against more transmissible SARS-CoV-2 variants.
- Published
- 2022
- Full Text
- View/download PDF
19. Rapid high-throughput compatible label-free virus particle quantification method based on time-resolved luminescence.
- Author
-
Kopra K, Hassan N, Vuorinen E, Valtonen S, Mahran R, Habib H, Jalkanen P, Susi P, Hytönen V, Hankaniemi M, Ylä-Herttuala S, Kakkola L, Peurla M, and Härmä H
- Subjects
- Humans, Luminescence, Virion, Virus Diseases, Viruses
- Abstract
Viruses play a major role in modern society and create risks from global pandemics and bioterrorism to challenges in agriculture. Virus infectivity assays and genome copy number determination methods are often used to obtain information on virus preparations used in diagnostics and vaccine development. However, these methods do not provide information on virus particle count. Current methods to measure the number of viral particles are often cumbersome and require highly purified virus preparations and expensive instrumentation. To tackle these problems, we developed a simple and cost-effective time-resolved luminescence-based method for virus particle quantification. This mix-and-measure technique is based on the recognition of the virus particles by an external Eu
3+ -peptide probe, providing results on virus count in minutes. The method enables the detection of non-enveloped and enveloped viruses, having over tenfold higher detectability for enveloped, dynamic range from 5E6 to 3E10 vp/mL, than non-enveloped viruses. Multiple non-enveloped and enveloped viruses were used to demonstrate the functionality and robustness of the Protein-Probe method., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
20. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.
- Author
-
Belik M, Jalkanen P, Lundberg R, Reinholm A, Laine L, Väisänen E, Skön M, Tähtinen PA, Ivaska L, Pakkanen SH, Häkkinen HK, Ortamo E, Pasternack A, Ritvos MA, Naves RA, Miettinen S, Sironen T, Vapalahti O, Ritvos O, Österlund P, Kantele A, Lempainen J, Kakkola L, Kolehmainen P, and Julkunen I
- Subjects
- 2019-nCoV Vaccine mRNA-1273, Antibodies, Neutralizing, Antibodies, Viral, BNT162 Vaccine, Humans, SARS-CoV-2, Vaccines, Synthetic, mRNA Vaccines, COVID-19 prevention & control, COVID-19 Vaccines
- Abstract
Two COVID-19 mRNA (of BNT162b2, mRNA-1273) and two adenovirus vector vaccines (ChAdOx1 and Janssen) are licensed in Europe, but optimization of regime and dosing is still ongoing. Here we show in health care workers (n = 328) that two doses of BNT162b2, mRNA-1273, or a combination of ChAdOx1 adenovirus vector and mRNA vaccines administrated with a long 12-week dose interval induce equally high levels of anti-SARS-CoV-2 spike antibodies and neutralizing antibodies against D614 and Delta variant. By contrast, two doses of BNT162b2 with a short 3-week interval induce 2-3-fold lower titers of neutralizing antibodies than those from the 12-week interval, yet a third BNT162b2 or mRNA-1273 booster dose increases the antibody levels 4-fold compared to the levels after the second dose, as well as induces neutralizing antibody against Omicron BA.1 variant. Our data thus indicates that a third COVID-19 mRNA vaccine may induce cross-protective neutralizing antibodies against multiple variants., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
21. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
- Author
-
Jalkanen P, Kolehmainen P, Haveri A, Huttunen M, Laine L, Österlund P, Tähtinen PA, Ivaska L, Maljanen S, Reinholm A, Belik M, Smura T, Häkkinen HK, Ortamo E, Kantele A, Julkunen I, Lempainen J, and Kakkola L
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, Antibody Formation, BNT162 Vaccine, COVID-19 Vaccines, Humans, RNA, Messenger, Spike Glycoprotein, Coronavirus, Vaccination, Vaccines, Synthetic, mRNA Vaccines, COVID-19 prevention & control, SARS-CoV-2 genetics
- Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has raised concern about increased transmissibility, infectivity, and immune evasion from a vaccine and infection-induced immune responses. Although COVID-19 mRNA vaccines have proven to be highly effective against severe COVID-19 disease, the decrease in vaccine efficacy against emerged Beta and Delta variants emphasizes the need for constant monitoring of new virus lineages and studies on the persistence of vaccine-induced neutralizing antibodies. To analyze the dynamics of COVID-19 mRNA vaccine-induced antibody responses, we followed 52 health care workers in Finland for 6 months after receiving two doses of BNT162b2 vaccine with a 3-week interval. We demonstrate that, although anti-S1 antibody levels decrease 2.3-fold compared to peak antibody levels, anti-SARS-CoV-2 antibodies persist for months after BNT162b2 vaccination. Variants D614G, Alpha, and Eta are neutralized by sera of 100% of vaccinees, whereas neutralization of Delta is 3.8-fold reduced and neutralization of Beta is 5.8-fold reduced compared to D614G. Despite this reduction, 85% of sera collected 6 months postvaccination neutralizes Delta variant. IMPORTANCE A decrease in vaccine efficacy against emerging SARS-CoV-2 variants has increased the importance of assessing the persistence of SARS-CoV-2 spike protein-specific antibodies and neutralizing antibodies. Our data show that after 6 months post two doses of BNT162b2 vaccine, antibody levels decrease yet remain detectable and capable of neutralizing emerging variants. By monitoring the vaccine-induced antibody responses, vaccination strategies and administration of booster doses can be optimized.
- Published
- 2022
- Full Text
- View/download PDF
22. Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients.
- Author
-
Hurme A, Jalkanen P, Heroum J, Liedes O, Vara S, Melin M, Teräsjärvi J, He Q, Pöysti S, Hänninen A, Oksi J, Vuorinen T, Kantele A, Tähtinen PA, Ivaska L, Kakkola L, Lempainen J, and Julkunen I
- Subjects
- Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, Humans, Leukocytes, Mononuclear, RNA, Messenger genetics, Spike Glycoprotein, Coronavirus, T-Lymphocytes, COVID-19, SARS-CoV-2
- Abstract
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants raise the question whether current vaccines can still protect against COVID-19 disease. We studied the dynamics and persistence of T cell responses using activation induced marker (AIM) assay and Th1 type cytokine production in peripheral blood mononuclear cells obtained from BNT162b2 COVID-19 mRNA vaccinated health care workers and COVID-19 patients. We demonstrate that equally high T cell responses following vaccination and infection persist at least for 6 months against Alpha, Beta, Gamma, and Delta variants despite the decline in antibody levels., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Hurme, Jalkanen, Heroum, Liedes, Vara, Melin, Teräsjärvi, He, Pöysti, Hänninen, Oksi, Vuorinen, Kantele, Tähtinen, Ivaska, Kakkola, Lempainen and Julkunen.)
- Published
- 2022
- Full Text
- View/download PDF
23. Filovirus VP24 Proteins Differentially Regulate RIG-I and MDA5-Dependent Type I and III Interferon Promoter Activation.
- Author
-
He FB, Khan H, Huttunen M, Kolehmainen P, Melén K, Maljanen S, Qu M, Jiang M, Kakkola L, and Julkunen I
- Subjects
- Cell Line, Tumor, DEAD Box Protein 58 genetics, Filoviridae genetics, Gene Expression Regulation immunology, HEK293 Cells, Humans, Interferon Type I genetics, Interferon-Induced Helicase, IFIH1 genetics, Interferons genetics, Interleukins genetics, Receptors, Immunologic genetics, Viral Proteins genetics, DEAD Box Protein 58 immunology, Filoviridae immunology, Interferon Type I immunology, Interferon-Induced Helicase, IFIH1 immunology, Interferons immunology, Interleukins immunology, Promoter Regions, Genetic immunology, Receptors, Immunologic immunology, Viral Proteins immunology
- Abstract
Filovirus family consists of highly pathogenic viruses that have caused fatal outbreaks especially in many African countries. Previously, research focus has been on Ebola, Sudan and Marburg viruses leaving other filoviruses less well studied. Filoviruses, in general, pose a significant global threat since they are highly virulent and potentially transmissible between humans causing sporadic infections and local or widespread epidemics. Filoviruses have the ability to downregulate innate immunity, and especially viral protein 24 (VP24), VP35 and VP40 have variably been shown to interfere with interferon (IFN) gene expression and signaling. Here we systematically analyzed the ability of VP24 proteins of nine filovirus family members to interfere with retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated antigen 5 (MDA5) induced IFN-β and IFN-λ1 promoter activation. All VP24 proteins were localized both in the cell cytoplasm and nucleus in variable amounts. VP24 proteins of Zaire and Sudan ebolaviruses, Lloviu, Taï Forest, Reston, Marburg and Bundibugyo viruses (EBOV, SUDV, LLOV, TAFV, RESTV, MARV and BDBV, respectively) were found to inhibit both RIG-I and MDA5 stimulated IFN-β and IFN-λ1 promoter activation. The inhibition takes place downstream of interferon regulatory factor 3 phosphorylation suggesting the inhibition to occur in the nucleus. VP24 proteins of Mengla (MLAV) or Bombali viruses (BOMV) did not inhibit IFN-β or IFN-λ1 promoter activation. Six ebolavirus VP24s and Lloviu VP24 bound tightly, whereas MARV and MLAV VP24s bound weakly, to importin α5, the subtype that regulates the nuclear import of STAT complexes. MARV and MLAV VP24 binding to importin α5 was very weak. Our data provides new information on the innate immune inhibitory mechanisms of filovirus VP24 proteins, which may contribute to the pathogenesis of filovirus infections., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 He, Khan, Huttunen, Kolehmainen, Melén, Maljanen, Qu, Jiang, Kakkola and Julkunen.)
- Published
- 2022
- Full Text
- View/download PDF
24. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
- Author
-
Solastie A, Virta C, Haveri A, Ekström N, Kantele A, Miettinen S, Lempainen J, Jalkanen P, Kakkola L, Dub T, Julkunen I, and Melin M
- Subjects
- Antibodies, Neutralizing immunology, COVID-19 diagnosis, Coronavirus Nucleocapsid Proteins immunology, Humans, Nucleoproteins, Phosphoproteins immunology, SARS-CoV-2, Sensitivity and Specificity, Antibodies, Viral immunology, COVID-19 Serological Testing methods, Fluorescent Antibody Technique methods, Immunoglobulin A immunology, Immunoglobulin G immunology, Immunoglobulin M immunology, Nucleocapsid Proteins immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Validation and standardization of accurate serological assays are crucial for the surveillance of the coronavirus disease 2019 (COVID-19) pandemic and population immunity. We describe the analytical and clinical performance of an in-house fluorescent multiplex immunoassay (FMIA) for simultaneous quantification of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein and spike glycoprotein. Furthermore, we calibrated IgG-FMIA against World Health Organization (WHO) International Standard and compared FMIA results to an in-house enzyme immunoassay (EIA) and a microneutralization test (MNT). We also compared the MNT results of two laboratories. IgG-FMIA displayed 100% specificity and sensitivity for samples collected 13 to 150 days post-onset of symptoms (DPO). For IgA- and IgM-FMIA, 100% specificity and sensitivity were obtained for a shorter time window (13 to 36 and 13 to 28 DPO for IgA- and IgM-FMIA, respectively). FMIA and EIA results displayed moderate to strong correlation, but FMIA was overall more specific and sensitive. IgG-FMIA identified 100% of samples with neutralizing antibodies (NAbs). Anti-spike IgG concentrations correlated strongly (ρ = 0.77 to 0.84, P < 2.2 × 10
-16 ) with NAb titers, and the two laboratories' NAb titers displayed a very strong correlation (ρ = 0.95, P < 2.2 × 10-16 ). Our results indicate good correlation and concordance of antibody concentrations measured with different types of in-house SARS-CoV-2 antibody assays. Calibration against the WHO international standard did not, however, improve the comparability of FMIA and EIA results. IMPORTANCE SARS-CoV-2 serological assays with excellent clinical performance are essential for reliable estimation of the persistence of immunity after infection or vaccination. In this paper we present a thoroughly validated SARS-CoV-2 serological assay with excellent clinical performance and good comparability to neutralizing antibody titers. Neutralization tests are still considered the gold standard for SARS-CoV-2 serological assays, but our assay can identify samples with neutralizing antibodies with 100% sensitivity and 96% specificity without the need for laborious and slow biosafety level 3 (BSL-3) facility-requiring analyses.- Published
- 2021
- Full Text
- View/download PDF
25. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
- Author
-
Jiang M, Kolehmainen P, Kakkola L, Maljanen S, Melén K, Smura T, Julkunen I, and Österlund P
- Subjects
- Angiotensin-Converting Enzyme 2, Antiviral Agents pharmacology, Cytokines genetics, Epithelial Cells virology, Gene Expression, Humans, Interferon Type I genetics, Interferons genetics, Kinetics, Lung virology, Phylogeny, RNA, Viral, SARS-CoV-2 classification, SARS-CoV-2 drug effects, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus, Trypsin, Interferon Lambda, COVID-19 immunology, Epithelial Cells immunology, Immunity, Innate, Lung immunology, SARS-CoV-2 isolation & purification, Virus Replication physiology
- Abstract
The primary target organ of coronavirus disease 2019 (COVID-19) infection is the respiratory tract. Currently, there is limited information on the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect and regulate innate immunity in human immune cells and lung epithelial cells. Here, we compared the ability of four Finnish isolates of SARS-CoV-2 from COVID-19 patients to replicate and induce interferons (IFNs) and other cytokines in different human cells. All isolates failed to replicate in dendritic cells, macrophages, monocytes, and lymphocytes, and no induction of cytokine gene expression was seen. However, most of the isolates replicated in Calu-3 cells, and they readily induced type I and type III IFN gene expression. The hCoV-19/Finland/FIN-25/2020 isolate, originating from a traveler from Milan in March 2020, showed better ability to replicate and induce IFN and inflammatory responses in Calu-3 cells than other isolates of SARS-CoV-2. Our data increase the knowledge on the pathogenesis and antiviral mechanisms of SARS-CoV-2 infection in human cell systems. IMPORTANCE With the rapid spread of the coronavirus disease 2019 (COVID-19) pandemic, information on the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulation of innate immunity in human immune cells and lung epithelial cells is needed. In the present study, we show that SARS-CoV-2 failed to productively infect human immune cells, but different isolates of SARS-CoV-2 showed differential ability to replicate and regulate innate interferon responses in human lung epithelial Calu-3 cells. These findings will open up the way for further studies on the mechanisms of pathogenesis of SARS-CoV-2 in human cells.
- Published
- 2021
- Full Text
- View/download PDF
26. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
- Author
-
Jalkanen P, Pasternack A, Maljanen S, Melén K, Kolehmainen P, Huttunen M, Lundberg R, Tripathi L, Khan H, Ritvos MA, Naves R, Haveri A, Österlund P, Kuivanen S, Jääskeläinen AJ, Kurkela S, Lappalainen M, Rantasärkkä K, Vuorinen T, Hytönen J, Waris M, Tauriainen S, Ritvos O, Kakkola L, and Julkunen I
- Subjects
- Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Humans, Immunoenzyme Techniques, Immunoglobulin A immunology, Immunoglobulin G immunology, Immunoglobulin M blood, Immunoglobulin M immunology, Neutralization Tests, Phosphoproteins immunology, SARS-CoV-2 immunology, Sensitivity and Specificity, COVID-19 diagnosis, COVID-19 Serological Testing methods, Coronavirus Nucleocapsid Proteins immunology, Immunoglobulin A blood, Immunoglobulin G blood, SARS-CoV-2 isolation & purification, Spike Glycoprotein, Coronavirus immunology
- Abstract
Background: Primary diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is based on detection of virus RNA in nasopharyngeal swab samples. In addition, analysis of humoral immunity against SARS-CoV-2 has an important role in viral diagnostics and seroprevalence estimates., Methods: We developed and optimized an enzyme immunoassays (EIA) using SARS-CoV-2 nucleoprotein (N), S1 and receptor binding domain (RBD) of the viral spike protein, and N proteins from SARS, Middle East respiratory syndrome (MERS), and 4 low-pathogenic human CoVs. Neutralizing antibody activity was compared with SARS-CoV-2 IgG, IgA, and IgM EIA results., Results: The sensitivity of EIA for detecting immune response in COVID-19 patients (n = 101) was 77% in the acute phase and 100% in the convalescent phase of SARS-CoV-2 infection when N and RBD were used as antigens in IgG and IgA specific EIAs. SARS-CoV-2 infection significantly increased humoral immune responses against the 229E and NL63 N proteins. S1 and RBD-based EIA results had a strong correlation with microneutralization test results., Conclusions: The data indicate a combination of SARS-CoV-2 S1 or RBD and N proteins and analysis of IgG and IgA immunoglobulin classes in sera provide an excellent basis for specific and sensitive serological diagnostics of COVID-19., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2021
- Full Text
- View/download PDF
27. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
- Author
-
Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, Maljanen S, Reinholm A, Tauriainen S, Pakkanen SH, Levonen I, Nousiainen A, Miller T, Välimaa H, Ivaska L, Pasternack A, Naves R, Ritvos O, Österlund P, Kuivanen S, Smura T, Hepojoki J, Vapalahti O, Lempainen J, Kakkola L, Kantele A, and Julkunen I
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Viral blood, Antibodies, Viral immunology, BNT162 Vaccine, Broadly Neutralizing Antibodies immunology, COVID-19 blood, COVID-19 epidemiology, COVID-19 immunology, COVID-19 Vaccines administration & dosage, Cross Protection immunology, Female, Finland epidemiology, Humans, Immunization, Secondary methods, Immunization, Secondary statistics & numerical data, Male, Mass Vaccination methods, Mass Vaccination statistics & numerical data, Middle Aged, Neutralization Tests statistics & numerical data, Reinfection immunology, Reinfection prevention & control, Reinfection virology, SARS-CoV-2 genetics, Young Adult, Broadly Neutralizing Antibodies blood, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunogenicity, Vaccine, SARS-CoV-2 immunology
- Abstract
As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces spike protein-specific neutralizing antibodies associated with protective immunity. The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates. Here we show, that after the second dose, the sera of BNT162b2-vaccinated health care workers (n = 180) effectively neutralize the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant, whereas the neutralization of the B.1.351 variant is five-fold reduced. Despite the reduction, 92% of the seronegative vaccinees have a neutralization titre of >20 for the B.1.351 variant indicating some protection. The vaccinees' neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides evidence that the second dose of the BNT162b2 vaccine induces cross-neutralization of at least some of the circulating SARS-CoV-2 variants.
- Published
- 2021
- Full Text
- View/download PDF
28. Comparison of Zaire ebolavirus realtime RT-PCRs targeting the nucleoprotein gene.
- Author
-
Jääskeläinen AJ, Sironen T, Kaloinen M, Kakkola L, Julkunen I, Hewson R, Weidmann MW, Mirazimi A, Watson R, and Vapalahti O
- Subjects
- Ebolavirus genetics, Humans, Limit of Detection, RNA, Viral genetics, Sensitivity and Specificity, Ebolavirus isolation & purification, Hemorrhagic Fever, Ebola diagnosis, Molecular Diagnostic Techniques, Nucleocapsid Proteins genetics, Polymerase Chain Reaction
- Abstract
In last five years, the Africa has faced two outbreaks of Zaire ebolavirus. These outbreaks have been the largest so far, and latest outbreak is still ongoing and affecting the Democratic Republic of the Congo. We tested in parallel three different Zaire ebolavirus (EBOV) realtime RT-PCRs targeting the nucleoprotein gene (EBOV NP-RT-qPCRs) described by Trombley et al. (2010); Huang et al. (2012) and Weidmann et al. (2004). These assays are used regularly in diagnostic laboratories. The limit of detection (LOD), intra-assay repeatability using different matrixes, sensitivity and specificity were determined. In addition, the primers and probes were aligned with the sequences available in ongoing and past outbreaks in order to check the mismatches. The specificity of all three EBOV NP-RT-qPCRs were excellent (100 %), and LODs were under or 10 copies per PCR reaction. Intra-assay repeatability was good in all assays, however the Ct-values were bit higher using the EDTA-blood based matrix. All of the primers and probes in EBOV NP-RT-qPCR assays have one or more mismatches in the probes and primers when the 2267 Zaire EBOV NP sequences, including strains Ituri from DRC outbreak (year 2018), was aligned. The EBOV strain of Bikoro (year 2018) circulating in DRC was 100 % match in Trombley and Weidmann assay, but had one mismatch in Huang assay., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
29. Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods.
- Author
-
Kazakova A, Kakkola L, Ziegler T, Syrjänen R, Päkkilä H, Waris M, Soukka T, and Julkunen I
- Subjects
- Adult, Hemagglutination Inhibition Tests, Humans, Immunoassay, Immunoenzyme Techniques, Immunoglobulin G immunology, Immunoglobulin M immunology, Antibodies, Viral immunology, Immunogenicity, Vaccine, Influenza Vaccines immunology, Influenza, Human epidemiology, Influenza, Human prevention & control
- Abstract
Influenza A viruses continue to circulate throughout the world as yearly epidemics or occasional pandemics. Influenza infections can be prevented by seasonal multivalent or monovalent pandemic vaccines. In the present study, we describe a novel multiplex microarray immunoassay (MAIA) for simultaneous measurement of virus-specific IgG and IgM antibodies using Pandemrix-vaccinated adult sera collected at day 0 and 28 and 180 days after vaccination as the study material. MAIA showed excellent correlation with a conventional enzyme immunoassay (EIA) in both IgG and IgM anti-influenza A antibodies and good correlation with hemagglutination inhibition (HI) test. Pandemrix vaccine induced 5-30 fold increases in anti-H1N1pdm09 influenza antibodies as measured by HI, EIA or MAIA. A clear increase in virus-specific IgG antibodies was found in 93-97% of vaccinees by MAIA and EIA. Virus-specific IgM antibodies were found in 90-92% of vaccinees by MAIA and EIA, respectively and IgM antibodies persisted for up to 6 months after vaccination in 55-62% of the vaccinees. Pandemic influenza vaccine induced strong anti-influenza A IgG and IgM responses that persisted several months after vaccination. MAIA was demonstrated to be an excellent method for simultaneous measurement of antiviral IgG and IgM antibodies against multiple virus antigens. Thus the method is well suitable for large scale epidemiological and vaccine immunity studies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
30. Zika Virus Non-Structural Protein NS5 Inhibits the RIG-I Pathway and Interferon Lambda 1 Promoter Activation by Targeting IKK Epsilon.
- Author
-
Lundberg R, Melén K, Westenius V, Jiang M, Österlund P, Khan H, Vapalahti O, Julkunen I, and Kakkola L
- Subjects
- Cell Line, DEAD Box Protein 58 metabolism, Humans, Interferon-beta genetics, Interferon-beta metabolism, Interferons metabolism, Interleukins metabolism, NF-kappa B metabolism, Phosphorylation, Promoter Regions, Genetic, Protein Binding, Receptors, Immunologic, Viral Nonstructural Proteins genetics, Zika Virus metabolism, Zika Virus Infection metabolism, Zika Virus Infection virology, I-kappa B Kinase metabolism, Interferon Regulatory Factor-3 metabolism, Interferons genetics, Interleukins genetics, Signal Transduction, Viral Nonstructural Proteins metabolism, Zika Virus physiology
- Abstract
The Zika virus (ZIKV) is a member of the Flaviviridae family and an important human pathogen. Most pathogenic viruses encode proteins that interfere with the activation of host innate immune responses. Like other flaviviruses, ZIKV interferes with the expression of interferon (IFN) genes and inhibits IFN-induced antiviral responses. ZIKV infects through epithelial barriers where IFN-λ1 is an important antiviral molecule. In this study, we analyzed the effects of ZIKV proteins on the activation of IFN-λ1 promoter. All ZIKV proteins were cloned and transiently expressed. ZIKV NS5, but no other ZIKV protein, was able to interfere with the RIG-I signaling pathway. This inhibition took place upstream of interferon regulatory factor 3 (IRF3) resulting in reduced phosphorylation of IRF3 and reduced activation of IFN-λ1 promoter. Furthermore, we showed that ZIKV NS5 interacts with the protein kinase IKKε, which is likely critical to the observed inhibition of phosphorylation of IRF3., Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2019
- Full Text
- View/download PDF
31. Asian and African lineage Zika viruses show differential replication and innate immune responses in human dendritic cells and macrophages.
- Author
-
Österlund P, Jiang M, Westenius V, Kuivanen S, Järvi R, Kakkola L, Lundberg R, Melén K, Korva M, Avšič-Županc T, Vapalahti O, and Julkunen I
- Subjects
- Africa, Asia, Dendritic Cells virology, Evolution, Molecular, Humans, Macrophages virology, Species Specificity, Zika Virus classification, Zika Virus immunology, Dendritic Cells immunology, Immunity, Innate, Macrophages immunology, Virus Replication, Zika Virus physiology
- Abstract
Zika virus (ZIKV) infections in humans are considered to be mild or subclinical. However, during the recent epidemics in the Pacific Islands and the Americas, the infection was associated with Quillain-Barré syndrome and congenital infections with fetal brain abnormalities, including microcephaly. Thus, more detailed understanding of ZIKV-host cell interactions and regulation of innate immune responses by strains of differential evolutionary origin is required. Here, we characterized the infection and immune responses triggered by two epidemic Asian/American lineage viruses, including an isolate from fetal brains, and a historical, low passage 1947 African lineage virus in human monocyte-derived dendritic cells (DCs) and macrophages. The epidemic Asian/American ZIKV replicated well and induced relatively good antiviral responses in human DCs whereas the African strain replicated less efficiently and induced weaker immune responses. In macrophages both the African and Asian strains showed limited replication and relatively weak cytokine gene expression. Interestingly, in macrophages we observed host protein degradation, especially IRF3 and STAT2, at early phases of infection with both lineage viruses, suggesting an early proteasomal activation in phagocytic cells. Our data indicates that ZIKV evolution has led to significant phenotypic differences in the replication characteristics leading to differential regulation of host innate immune responses.
- Published
- 2019
- Full Text
- View/download PDF
32. Serological Array-in-Well Multiplex Assay Reveals a High Rate of Respiratory Virus Infections and Reinfections in Young Children.
- Author
-
Kazakova A, Kakkola L, Päkkilä H, Teros-Jaakkola T, Soukka T, Peltola V, Waris M, and Julkunen I
- Subjects
- Adenoviridae immunology, Child, Preschool, Cohort Studies, Humans, Immunoassay methods, Infant, Influenza A virus immunology, Influenza B virus immunology, Microarray Analysis, Observational Studies as Topic, Respiratory Syncytial Viruses immunology, Respiratory Tract Infections immunology, Antibodies, Viral blood, High-Throughput Screening Assays methods, Respiratory Tract Infections virology, Serologic Tests methods, Viruses immunology
- Abstract
Serological assays are used to diagnose and characterize host immune responses against microbial pathogens. Microarray technologies facilitate high-throughput immunoassays of antibody detection against multiple pathogens simultaneously. To improve survey of influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV), and adenovirus (AdV) antibody levels, we developed a microarray consisting of IAV H1N1, IAV H1N1pdm09 (vaccine), IAV H3N2, IBV Victoria, IBV Yamagata, RSV, AdV type 5 hexon protein, and control antigens printed on the bottom of a microtiter plate well. Bound IgG antibodies were detected with anti-human IgG-coated photon-upconverting nanoparticles and measured with a photoluminescence imager. The performance of the microarray immunoassay (MAIA) was evaluated with serum samples ( n = 576) collected from children ( n = 288) at 1 and 2 years of age and tested by standard enzyme immunoassays (EIAs) for antibodies to IAV vaccine and RSV. EIAs and MAIA showed substantial to almost perfect agreement (Cohen's κ, 0.62 to 0.83). Applying MAIA, we found seroprevalences of 55% for IAV H1N1, 54% for IAV vaccine, 30% for IAV H3N2, 24% for IBV Victoria, 25% for IBV Yamagata, 38% for RSV, and 26% for AdV in 1-year-old children ( n = 768). By the age of 2 years, IgG seropositivity rates ( n = 714) increased to 74% for IAV H1N1, 71% for IAV vaccine, 49% for IAV H3N2, 47% for IBV Yamagata, 49% for IBV Victoria, 68% for RSV, and 58% for AdV. By analyzing increases in antibody levels not biased by vaccinations, we found a reinfection rate of 40% for RSV and 31% for AdV in children between 1 and 2 years of age. IMPORTANCE The multiplex immunoassay was successfully used to simultaneously detect antibodies against seven different viruses. The developed serological microarray is a new promising tool for diagnostic, epidemiological, and seroprevalence analyses of virus infections., (Copyright © 2019 Kazakova et al.)
- Published
- 2019
- Full Text
- View/download PDF
33. Novel activities of safe-in-human broad-spectrum antiviral agents.
- Author
-
Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, and Kainov D
- Subjects
- Drug Repositioning, Humans, Antiviral Agents pharmacology, DNA Viruses drug effects, RNA Viruses drug effects, Virus Diseases drug therapy
- Abstract
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
34. Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.
- Author
-
Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, and Kainov DE
- Subjects
- Aniline Compounds pharmacology, Antiviral Agents chemistry, Antiviral Agents therapeutic use, Benzothiazoles chemistry, Benzothiazoles therapeutic use, Cell Line, DNA, Viral genetics, Humans, Isoquinolines chemistry, Isoquinolines therapeutic use, Metabolomics, RNA, Viral genetics, Sulfonamides pharmacology, Transfection, Virus Diseases drug therapy, Virus Diseases prevention & control, Antiviral Agents pharmacology, Apoptosis drug effects, Benzothiazoles pharmacology, Isoquinolines pharmacology, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Virus Replication drug effects, Viruses drug effects
- Abstract
Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity, antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention and treatment of viral diseases., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2017
- Full Text
- View/download PDF
35. Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-λ1 gene expression.
- Author
-
He F, Melén K, Maljanen S, Lundberg R, Jiang M, Österlund P, Kakkola L, and Julkunen I
- Subjects
- Cell Line, Gene Expression Regulation, Humans, Interferons, Ebolavirus immunology, Ebolavirus pathogenicity, Host-Pathogen Interactions, Immune Evasion, Immunity, Innate, Interleukins antagonists & inhibitors, Viral Proteins metabolism
- Abstract
Ebolaviruses (EBOV) cause severe disease with a recent outbreak in West Africa in 2014-2015 leading to more than 28 000 cases and 11 300 fatalities. This emphasizes the urgent need for better knowledge on these highly pathogenic RNA viruses. Host innate immune responses play a key role in restricting the spread of a viral disease. In this study we systematically analyzed the effects of cloned EBOV genes on the main host immune response to RNA viruses: the activation of RIG-I pathway and type I and III interferon (IFN) gene expression. EBOV VP24, in addition of inhibiting IFN-induced antiviral responses, was found to efficiently inhibit type III IFN-λ1 gene expression. This inhibition was found to occur downstream of IRF3 activation and to be dependent on VP24 importin binding residues. These results emphasize the importance of VP24 in EBOV infection cycle, making VP24 as an excellent target for drug development., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
36. Production, purification and immunogenicity of recombinant Ebola virus proteins - A comparison of Freund's adjuvant and adjuvant system 03.
- Author
-
Melén K, Kakkola L, He F, Airenne K, Vapalahti O, Karlberg H, Mirazimi A, and Julkunen I
- Subjects
- Animals, Antibodies, Viral biosynthesis, Antibodies, Viral blood, Antibodies, Viral immunology, Baculoviridae genetics, Drug Combinations, Ebolavirus chemistry, Ebolavirus isolation & purification, Guinea Pigs, Rabbits, Recombinant Proteins immunology, Recombinant Proteins isolation & purification, Viral Proteins genetics, Adjuvants, Immunologic, Ebolavirus immunology, Freund's Adjuvant supply & distribution, Polysorbates, Squalene, Viral Proteins immunology, Viral Proteins isolation & purification, alpha-Tocopherol
- Abstract
There is an urgent need for Ebola virus (EBOV) proteins, EBOV-specific antibodies and recombinant antigens to be used in diagnostics and as potential vaccine candidates. Our objective was to produce and purify recombinant proteins for immunological assays and for the production of polyclonal EBOV specific antibodies. In addition, a limited comparison of the adjuvant effects of Freund's complete adjuvant (FCA) and adjuvant system 03 (AS03) was carried out. Recombinant EBOV GST-VP24, -VP30, -VP35, -VP40 and -NP were produced in E. coli and purified with affinity chromatography followed by preparative gel electrophoresis. Recombinant EBOV GP-His was produced in Sf9 insect cells and purified by preparative gel electrophoresis. To compare the adjuvant effect of FCA and AS03, 12 rabbits were immunized four times with one of the six recombinant EBOV proteins using FCA or AS03. In addition, three guinea pigs were immunized with EBOV VP24 using FCA. With the exception of sera from two rabbits immunized with GST-VP24, the antisera against all other EBOV proteins showed very high and specific antibody responses after three to four immunizations. The adjuvant effect of AS03 was comparable to that of FCA. The produced antibodies recognized the corresponding EBOV proteins in wild type EBOV-infected cells., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
37. Protein profiling of nasopharyngeal aspirates of hospitalized and outpatients revealed cytokines associated with severe influenza A(H1N1)pdm09 virus infections: A pilot study.
- Author
-
Fu Y, Gaelings L, Jalovaara P, Kakkola L, Kinnunen MT, Kallio-Kokko H, Valkonen M, Kantele A, and Kainov DE
- Subjects
- Adult, Basigin analysis, Female, Hospitalization, Humans, Immunity, Innate, Influenza, Human diagnosis, Influenza, Human epidemiology, Male, Middle Aged, Nasopharynx virology, Outpatients, Pilot Projects, Protein Array Analysis, Retinol-Binding Proteins, Plasma analysis, Severity of Illness Index, Trefoil Factor-3 analysis, Chemokines analysis, Cytokines analysis, Influenza A Virus, H1N1 Subtype immunology, Influenza, Human immunology, Influenza, Human virology, Nasopharynx immunology
- Abstract
Influenza A viruses (IAV) mutate rapidly and cause seasonal epidemics and occasional pandemics, which result in substantial number of patient visits to the doctors and even hospitalizations. We aimed here to identify inflammatory proteins, which levels correlated to clinical severity of the disease. For this we analysed 102 cytokines and growth factors in human nasopharyngeal aspirate (NPA) samples of 27 hospitalized and 27 outpatients diagnosed with influenza A(H1N1)pdm09 virus infection. We found that the relative levels of monocyte differentiation antigen CD14, lipocalin-2 (LCN2), C-C-motif chemokine 20 (CCL20), CD147, urokinase plasminogen activator surface receptor (uPAR), pro-epidermal growth factor (EGF), trefoil factor 3 (TFF3), and macrophage migration inhibitory factor (MIF) were significantly lower (p<0.008), whereas levels of retinol-binding protein 4 (RBP4), C-X-C motif chemokine 5 (CXCL5), interleukin-8 (IL-8), complement factor D (CFD), adiponectin, and chitinase-3-like 1 (CHI3L1) were significantly higher (p<0.008) in NPA samples of hospitalized than non-hospitalized patients. While changes in CD14, LCN2, CCL20, uPAR, EGF, MIF, CXCL5, IL-8, adiponectin and CHI3L1 levels have already been correlated with severity of IAV infection in mice and humans, our study is the first to describe association of CD147, RBP4, TFF3, and CFD with hospitalization of IAV-infected patients. Thus, we identified local innate immune profiles, which were associated with the clinical severity of influenza infections., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
38. Comparative Analysis of Whole-Genome Sequences of Influenza A(H1N1)pdm09 Viruses Isolated from Hospitalized and Nonhospitalized Patients Identifies Missense Mutations That Might Be Associated with Patient Hospital Admissions in Finland during 2009 to 2014.
- Author
-
Mishel P, Ojala T, Benner C, Lakspere T, Bychkov D, Jalovaara P, Kakkola L, Kallio-Kokko H, Kantele A, Kankainen M, Ikonen N, Ripatti S, Julkunen I, and Kainov DE
- Abstract
Here, we report 40 new whole-genome sequences of influenza A(H1N1)pdm09 viruses isolated from Finnish patients during 2009 to 2014. A preliminary analysis of these and 186 other whole genomes of influenza A(H1N1)pdm09 viruses isolated from hospitalized and nonhospitalized patients during 2009 to 2014 in Finland revealed several viral mutations that might be associated with patient hospitalizations., (Copyright © 2015 Mishel et al.)
- Published
- 2015
- Full Text
- View/download PDF
39. Complete Genome Sequences of Influenza A/H1N1 Strains Isolated from Patients during the 2013-2014 Epidemic Season in Finland.
- Author
-
Jalovaara P, Mishel P, Kallio-Kokko H, Valkonen M, Kantele A, Ikonen N, Julkunen I, Kakkola L, Kutsaya A, Vuorinen T, Mattila P, Almusa H, and Kainov D
- Abstract
Here, we report 40 complete genome sequences of influenza A/H1N1 strains isolated from 33 nonhospitalized and 7 hospitalized patients during the 2013-2014 epidemic season in Finland. An analysis of the aligned sequences revealed no oseltamivir-resistant genotypes. As a whole, the recent viruses have drifted from the prototype A/California/7/2009 virus by ca. 1.3%., (Copyright © 2015 Jalovaara et al.)
- Published
- 2015
- Full Text
- View/download PDF
40. Full-Genome Sequences of Influenza H3N2 Virus Strains Isolated from Finnish Patients during the 2012-2013 Epidemic Season.
- Author
-
Lakspere T, Kallio-Kokko H, Kantele A, Mattila P, Almusa H, Kainov D, and Kakkola L
- Abstract
Here, we sequenced 10 influenza A(H3N2) virus genomes isolated from Finnish patients diagnosed with flu-like illness during the 2012-2013 influenza season. The alignment showed a high number of amino acid substitutions (238 in total) in only 10 samples, proving that a high mutation rate exists in seasonal influenza A viruses.
- Published
- 2014
- Full Text
- View/download PDF
41. Full-Genome Sequences of Influenza A(H1N1)pdm09 Viruses Isolated from Finnish Patients from 2009 to 2013.
- Author
-
Lakspere T, Tynell J, Kaloinen M, Vanlede M, Parsons A, Ikonen N, Kallio-Kokko H, Kantele A, Mattila P, Almusa H, Julkunen I, Kainov D, and Kakkola L
- Abstract
Here we report full-length sequencing of the first large set of influenza A(H1N1)pdm09 virus genomes isolated in Finland between the years 2009 and 2013 and discuss the advantages and needs of influenza virus sequencing efforts.
- Published
- 2014
- Full Text
- View/download PDF
42. Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles.
- Author
-
Bimbo LM, Denisova OV, Mäkilä E, Kaasalainen M, De Brabander JK, Hirvonen J, Salonen J, Kakkola L, Kainov D, and Santos HA
- Subjects
- Animals, Dogs, Drug Carriers, Drug Delivery Systems, Humans, Madin Darby Canine Kidney Cells, Microscopy, Fluorescence, Models, Chemical, Particle Size, Solvents chemistry, Amides administration & dosage, Influenza A virus drug effects, Influenza, Human drug therapy, Nanoparticles chemistry, Nanotechnology methods, Salicylates administration & dosage, Silicon chemistry
- Abstract
Influenza A viruses (IAVs) cause recurrent epidemics in humans, with serious threat of lethal worldwide pandemics. The occurrence of antiviral-resistant virus strains and the emergence of highly pathogenic influenza viruses have triggered an urgent need to develop new anti-IAV treatments. One compound found to inhibit IAV, and other virus infections, is saliphenylhalamide (SaliPhe). SaliPhe targets host vacuolar-ATPase and inhibits acidification of endosomes, a process needed for productive virus infection. The major obstacle for the further development of SaliPhe as antiviral drug has been its poor solubility. Here, we investigated the possibility to increase SaliPhe solubility by loading the compound in thermally hydrocarbonized porous silicon (THCPSi) nanoparticles. SaliPhe-loaded nanoparticles were further investigated for the ability to inhibit influenza A infection in human retinal pigment epithelium and Madin-Darby canine kidney cells, and we show that upon release from THCPSi, SaliPhe inhibited IAV infection in vitro and reduced the amount of progeny virus in IAV-infected cells. Overall, the PSi-based nanosystem exhibited increased dissolution of the investigated anti-IAV drug SaliPhe and displayed excellent in vitro stability, low cytotoxicity, and remarkable reduction of viral load in the absence of organic solvents. This proof-of-principle study indicates that PSi nanoparticles could be used for efficient delivery of antivirals to infected cells.
- Published
- 2013
- Full Text
- View/download PDF
43. Molecular evolution and epidemiology of echovirus 6 in Finland.
- Author
-
Smura T, Kakkola L, Blomqvist S, Klemola P, Parsons A, Kallio-Kokko H, Savolainen-Kopra C, Kainov DE, and Roivainen M
- Subjects
- Animals, Capsid Proteins genetics, Cell Line, Tumor, Chlorocebus aethiops, Cluster Analysis, Echovirus 6, Human classification, Echovirus 6, Human isolation & purification, Finland epidemiology, Humans, Molecular Epidemiology, Phylogeny, Recombination, Genetic, Sequence Analysis, Protein, Sewage virology, Echovirus 6, Human genetics, Echovirus Infections epidemiology, Echovirus Infections virology, Evolution, Molecular
- Abstract
Echovirus 6 (E-6) (family Picornaviridae, genus Enterovirus) is one of the most commonly detected enteroviruses worldwide. The aim of this study was to determine molecular evolutionary and epidemiologic patterns of E-6. A complete genome of one E-6 strain and the partial VP1 coding regions of 169 strains were sequenced and analyzed along with sequences retrieved from the GenBank. The complete genome sequence analysis suggested complex recombination history for the Finnish E-6 strain. In VP1 region, the phylogenetic analysis suggested three major clusters that were further divided to several subclusters. The evolution of VP1 coding region was dominated by negative selection suggesting that the phylogeny of E-6 VP1 gene is predominantly a result of synonymous substitutions (i.e. neutral genetic drift). The partial VP1 sequence analysis suggested wide geographical distribution for some E-6 lineages. In Finland, multiple different E-6 lineages have circulated at the same time., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
44. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.
- Author
-
Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, and Kainov DE
- Subjects
- Animals, Chlorocebus aethiops, Deoxycytidine pharmacology, Dogs, Humans, Indoles, Influenza, Human metabolism, Myeloid Cell Leukemia Sequence 1 Protein, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Proto-Oncogene Proteins c-bcl-2 metabolism, RNA, Viral biosynthesis, Vero Cells, Virus Replication, Gemcitabine, Amides pharmacology, Antiviral Agents pharmacology, Deoxycytidine analogs & derivatives, Influenza A Virus, H3N2 Subtype drug effects, Influenza A Virus, H3N2 Subtype physiology, Influenza, Human drug therapy, Pyrroles pharmacology, Salicylates pharmacology
- Abstract
Influenza A viruses (IAVs) infect humans and cause significant morbidity and mortality. Different treatment options have been developed; however, these were insufficient during recent IAV outbreaks. Here, we conducted a targeted chemical screen in human nonmalignant cells to validate known and search for novel host-directed antivirals. The screen validated saliphenylhalamide (SaliPhe) and identified two novel anti-IAV agents, obatoclax and gemcitabine. Further experiments demonstrated that Mcl-1 (target of obatoclax) provides a novel host target for IAV treatment. Moreover, we showed that obatoclax and SaliPhe inhibited IAV uptake and gemcitabine suppressed viral RNA transcription and replication. These compounds possess broad spectrum antiviral activity, although their antiviral efficacies were virus-, cell type-, and species-specific. Altogether, our results suggest that phase II obatoclax, investigational SaliPhe, and FDA/EMEA-approved gemcitabine represent potent antiviral agents.
- Published
- 2012
- Full Text
- View/download PDF
45. Emerging cellular targets for influenza antiviral agents.
- Author
-
Müller KH, Kakkola L, Nagaraj AS, Cheltsov AV, Anastasina M, and Kainov DE
- Subjects
- Antiviral Agents therapeutic use, Humans, Influenza A virus physiology, Influenza, Human drug therapy, Influenza, Human virology, Virus Replication drug effects, Antiviral Agents pharmacology, Influenza A virus drug effects
- Abstract
At the global level, influenza A virus (IAV) is considered a major health threat because it causes significant morbidity. Different treatment and prevention options have been developed; however, these are insufficient in the face of recent IAV outbreaks. In particular, available antiviral agents have limited effectiveness owing to IAV resistance to these virus-directed drugs. Recent advances in understanding of IAV replication have revealed a number of cellular drug targets that counteract viral drug resistance. This review summarizes current knowledge on IAV replication with a focus on emerging cellular drug targets. Interestingly, for many of these targets, compounds for which safety testing has been carried out in humans are available. It is possible that some of these compounds, such as inhibitors of heat shock protein 90, proteasome, importin α5 or protein kinase C, will be used for treatment of IAV infections after careful evaluation in human primary cells and severely ill flu patients., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
46. Expression of all six human Torque teno virus (TTV) proteins in bacteria and in insect cells, and analysis of their IgG responses.
- Author
-
Kakkola L, Bondén H, Hedman L, Kivi N, Moisala S, Julin J, Ylä-Liedenpohja J, Miettinen S, Kantola K, Hedman K, and Söderlund-Venermo M
- Subjects
- Adult, Animals, Antibodies, Viral biosynthesis, Antigens, Viral biosynthesis, Antigens, Viral genetics, Base Sequence, Cell Line, DNA Virus Infections immunology, DNA Virus Infections virology, DNA, Viral genetics, Escherichia coli genetics, Gene Expression, Genes, Viral, Humans, Immunoglobulin G biosynthesis, Molecular Sequence Data, Open Reading Frames, Recombinant Proteins biosynthesis, Recombinant Proteins genetics, Recombinant Proteins immunology, Spodoptera, Viral Proteins biosynthesis, Torque teno virus genetics, Torque teno virus immunology, Viral Proteins genetics, Viral Proteins immunology
- Abstract
Torque teno virus (TTV) is a non-enveloped human virus with a circular ( approximately 3800 nt) ssDNA genome. TTV transcription results in three viral mRNAs and six proteins, the function or antigenicity of which are unknown. The six open reading frames of TTV genotype 6 were expressed in bacteria and insect cells. Expression of the ORF1/1-encoded protein was inefficient, while expression of the others was successful, with ORF1 and ORF1/2 as arginine-rich region depleted. All six recombinant TTV proteins were antigenic. Of healthy adults, 11/25 (44%) showed strong IgG reactivity with one or more proteins. Four subjects, two of whom were genotype-6-DNA positive, were followed. One of the latter showed concurrently a strong IgG response against the ORF1 protein. The other showed appearance of IgG against the ORF2 protein concomitantly with resolution of the genotype-6 viremia. The genotype-6 sequences remained unaltered for years, suggesting that some mechanisms other than amino acid substitutions play a role in TTV immune evasion.
- Published
- 2008
- Full Text
- View/download PDF
47. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones.
- Author
-
Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, Kakkola L, Söderlund-Venermo M, Young NS, and Brown KE
- Subjects
- Amino Acid Sequence, Capsid Proteins chemistry, Capsid Proteins genetics, Cell Line, Child, Humans, Molecular Sequence Data, Mutation, Parvovirus B19, Human enzymology, Parvovirus B19, Human genetics, Phospholipases A2 chemistry, Phospholipases A2 genetics, Sequence Analysis, DNA, Capsid Proteins metabolism, Cloning, Molecular, Genome, Viral, Parvovirus B19, Human pathogenicity, Phospholipases A2 metabolism
- Abstract
Three full-length genomic clones (pB19-M20, pB19-FL and pB19-HG1) of parvovirus B19 were produced in different laboratories. pB19-M20 was shown to produce infectious virus. To determine the differences in infectivity, all three plasmids were tested by transfection and infection assays. All three clones were similar in viral DNA replication, RNA transcription, and viral capsid protein production. However, only pB19-M20 and pB19-HG1 produced infectious virus. Comparison of viral sequences showed no significant differences in ITR or NS regions. In the capsid region, there was a nucleotide sequence difference conferring an amino acid substitution (E176K) in the phospholipase A2-like motif of the VP1-unique (VP1u) region. The recombinant VP1u with the E176K mutation had no catalytic activity as compared with the wild-type. When this mutation was introduced into pB19-M20, infectivity was significantly attenuated, confirming the critical role of this motif. Investigation of the original serum from which pB19-FL was cloned confirmed that the phospholipase mutation was present in the native B19 virus.
- Published
- 2008
- Full Text
- View/download PDF
48. Construction and biological activity of a full-length molecular clone of human Torque teno virus (TTV) genotype 6.
- Author
-
Kakkola L, Tommiska J, Boele LC, Miettinen S, Blom T, Kekarainen T, Qiu J, Pintel D, Hoeben RC, Hedman K, and Söderlund-Venermo M
- Subjects
- Aphidicolin pharmacology, Cell Line, Cloning, Molecular, DNA Replication drug effects, DNA, Viral biosynthesis, DNA, Viral genetics, Genotype, Humans, Molecular Sequence Data, RNA, Viral biosynthesis, RNA, Viral genetics, Sequence Analysis, DNA, Torque teno virus classification, Torque teno virus drug effects, DNA, Recombinant genetics, Genome, Viral genetics, Torque teno virus genetics, Torque teno virus physiology
- Abstract
Torque teno virus (TTV) is a non-enveloped human virus with a circular negative-sense (approximately 3800 nucleotides) ssDNA genome. TTV resembles in genome organization the chicken anemia virus, the animal pathogen of the Circoviridae family, and is currently classified as a member of a new, floating genus, Anellovirus. Molecular and cell biological research on TTV has been restricted by the lack of permissive cell lines and functional, replication-competent plasmid clones. In order to examine the key biological activities (i.e. RNA transcription and DNA replication) of this still poorly characterized ssDNA virus, we cloned the full-length genome of TTV genotype 6 and transfected it into cells of several types. TTV mRNA transcription was detected by RT-PCR in all the cell types: KU812Ep6, Cos-1, 293, 293T, Chang liver, Huh7 and UT7/Epo-S1. Replicating TTV DNA was detected in the latter five cell types by a DpnI-based restriction enzyme method coupled with Southern analysis, a novel approach to assess TTV DNA replication. The replicating full-length clone, the cell lines found to support TTV replication, and the methods presented here will facilitate the elucidation of the molecular biology and the life cycle of this recently identified human virus.
- Published
- 2007
- Full Text
- View/download PDF
49. Biological and immunological relations among human parvovirus B19 genotypes 1 to 3.
- Author
-
Ekman A, Hokynar K, Kakkola L, Kantola K, Hedman L, Bondén H, Gessner M, Aberham C, Norja P, Miettinen S, Hedman K, and Söderlund-Venermo M
- Subjects
- Antibodies, Viral blood, Baculoviridae, Capsid Proteins genetics, Genotype, HeLa Cells, Hemagglutination genetics, Humans, Parvoviridae Infections blood, Parvoviridae Infections genetics, Parvovirus B19, Human genetics, Promoter Regions, Genetic genetics, Promoter Regions, Genetic immunology, Species Specificity, U937 Cells, Antibodies, Viral immunology, Capsid immunology, Capsid Proteins immunology, Hemagglutination immunology, Parvoviridae Infections immunology, Parvovirus B19, Human immunology
- Abstract
The human parvovirus B19 is now divided into three genotypes: type 1 (prototype), type 2 (A6- and LaLi-like), and type 3 (V9-like). In overall DNA sequence, the three virus types differ by approximately 10%. The most striking DNA dissimilarity, of >20%, is observed within the p6 promoter region. Because of the scarcity of data on the biological activities and pathogenetic potentials of virus types 2 and 3, we examined the functional characteristics of these virus types. We found the activities of the three p6 promoters to be of equal strength and to be most active in B19-permissive cells. Virus type 2 capsid protein VP2, alone or together with VP1, was expressed with the baculovirus system and was shown to assemble into icosahedral parvovirus-like particles, which were reactive in the hemagglutination assay. Furthermore, sera containing DNA of any of the three B19 types were shown to hemagglutinate. The infectivities of these sera were examined in two B19-permissive cell lines. Reverse transcription-PCR revealed synthesis of spliced B19 mRNAs, and immunofluorescence verified the production of NS and VP proteins in the infected cells. All three genotypes showed similar functional characteristics in all experiments performed, showing that the three virus types indeed belong to the same species, i.e., human parvovirus B19. Additionally, the antibody activity in sera from B19 type 1- or type 2-infected subjects (long-term immunity) was examined with homo- and heterologous virus-like particles. Cross-reactivity of 100% was observed, indicating that the two B19 genotypes comprise a single serotype.
- Published
- 2007
- Full Text
- View/download PDF
50. Human circovirus TT virus genotype 6 expresses six proteins following transfection of a full-length clone.
- Author
-
Qiu J, Kakkola L, Cheng F, Ye C, Söderlund-Venermo M, Hedman K, and Pintel DJ
- Subjects
- Cell Line, Cell Nucleus metabolism, Cytoplasm metabolism, Humans, Molecular Sequence Data, Torque teno virus genetics, Transfection, Torque teno virus metabolism, Viral Proteins metabolism
- Abstract
The expression profile of the circovirus TTV has not yet been fully characterized. In this paper, we show that following transfection of a full-length viral clone of TTV genotype 6, each of the three virally encoded mRNAs is translated from two initiating AUGs, and therefore, the TTV genome generates at least six proteins. Localization studies of hemagglutinin-tagged versions of these proteins in fixed cells, and green fluorescent protein-tagged versions of these proteins in living cells, expressed following transfection, demonstrated that two were primarily nuclear, two were primarily cytoplasmic, and two were found throughout the cell.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.